(Reuters) -Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the ...

Volt™ PFA System enrollment wraps up, TactiFlex™ Duo trial begins, and Advisor™ HD Grid X gains FDA clearance!Portland, ...

The following is a summary of “Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes,” published in the ...

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

The study, published Monday in the American Heart Association journal Circulation, suggests digital heart twins could offer a ...

BACKGROUND: Current outcomes from catheter ablation for scar-dependent ventricular tachycardia (VT) are limited by high ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

Jaswant Kaur finds permanent relief from heart condition through successful Radiofrequency Catheter Ablation at NIMS ...

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.